Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: A systematic review and meta-analysis;Eficacia clínica del moxifloxacino en el tratamiento de las agudizaciones de la bronquitis crónica. Revisión sistemática y metaanálisis

Archivos de Bronconeumologia

Volumn 43, Issue 1, 2007, Pages 22-28

  Miravitlles, Marc ^a   Molina, Jesús ^b   Brosa, Max ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b Centro de Salud Francia   (Spain)

^c Oblikue Consulting   (Spain)

Author keywords

Antibiotics; Chronic bronchitis; Exacerbations; Meta analysis; Moxifloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; LEVOFLOXACIN; MOXIFLOXACIN;

ARTICLE; BACTERICIDAL ACTIVITY; BIOEQUIVALENCE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; ERADICATION THERAPY; FOLLOW UP; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

EID: 33846905504     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13096997     Document Type: Article

References (40)

1. Miravitlles M. El fracaso en el tratamiento de las agudizaciones de la enfermedad pulmonar obstructiva crónica. Factores de riesgo e importancia clínica. Med Clin (Barc). 2002;119:304-14.
2. Masa JF, Sobradillo V, Villasante C, Jiménez-Ruiz CA, Fernández-Fau L, Viejo JL, et al. Costes de la EPOC en España. Estimación a partir de un estudio epidemiológico poblacional. Arch Bronconeumol. 2004;40:72-9.
3. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest. 2003;123:784-91.
4. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449-55.
5. Izquierdo Alonso JL, De Miguel Díez J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. Journal of COPD. 2004;1:215-33.
6. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
7. Miravitlles M, Torres A. Antibiotics in exacerbations of COPD: lessons from the past. Eur Respir J. 2004;24:896-7.
8. Miravitlles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother. 2005;6:283-93.
9. th European Congress of Clinical Microbiology and Infectious Diseases; 1999; Berlin.
10. Landen H, Möller M, Tillotson GS, Kubin R, Hoffken G. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res. 2001;29:51-60.
11. Lorenz J, Busch W, Thate-Waschke IM. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. Fortschr Med Orig. 2000;118 Suppl 2:63-70.
12. Lorenz J, Busch W, Thate-Waschke IM, Therapy study of acute exacerbated chronic bronchitis. Quinolone rapidly improves cough and chest pain. BRONCHIMOX Study Group. Fortschr Med. 2000;142:35-40.
13. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J, for the EFEMAP study group. The effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in Primary Care. Clin Drug Invest. 2004;24:63-72.
14. Llor C, Naberan K, Cots JM, Molina J, Miravitlles M. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care centers. Int J Clin Pract. 2004;58:937-44.
15. Li-Mcleod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface. 2001;4:52-9.
16. Lorenz J, Busch W, Thate-Waschke IM. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res. 2001;29:61-73.
17. Miravitlles M, Ros F, Cobos A, Kubin R, Tillotson G. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis; a Spanish physician and patient experience. Int J Clin Pract. 2001;55:437-41.
18. Miravitlles M, Llor C, Naberan K, Cots JM, Molina J. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med. 2005;99:955-65.
19. Miravitlles M, Zalacain R, Murio C, Álvarez-Sala JL, Masa JF, Verea H, et al. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two-year study. Clin Drug Invest. 2003;23:439-50.
20. Lorenz J, Thate-Waschke IM, Mast O, Kubin R, Rychlik R, Pfeil T, et al. Treatment outcomes in acute exacerbation of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res. 2001;29:74-86.
21. Wilson R, Kubin R, Ballin I, Deppermann KM, Bassaris HP, Leophonte P, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44:501-13.
22. Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis, the Bronchitis Study Group. Respir Med. 2000;94:18-27.
23. DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med. 2000;94:1029-37.
24. Hautamaki D, Bruya T, Kureishi A, Warner J, Church D. Short-course (5-day) moxifloxacin versus 7-day levofloxacin therapy for treatment of acute exacerbations of chronic bronchitis. Today's Therapeutic Trends. 2001;19:117-36.
25. Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953-64.
26. Starakis I, Gogos CA, Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2004;23:129-37.
27. Kreis SR, Herrera N, Golzar N, Fuller D, Heyd A. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Manag. 2000;7:33-7.
28. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P for the AECB Study Group. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with amoxicillin-clavulanate oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res. 2001;29:314-28.
29. Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G, for the Smart Study Group. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother. 2002;14:597-608.
30. 1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003;138:969-73.
31. Sutherland ER, Allmenrs H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58:937-41.
32. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J. 2002;20 Suppl 36:9-19.
33. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest. 2005;127:2231-6.
34. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:639-52.
35. Lode H, Eller J, Linnhoff A, Ioanas M and the ETIC Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on infection-free interval. Eur Respir J. 2004;24:947-53.
36. Donaldson GC, Seemungal TAR, Bhomik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57: 847-52.
37. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa JF, et al. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax. 2004;59:387-95.
38. Miravitlles M. Designing future clinical trials for acute exacerbations of chronic bronchitis. En: Allegra L, Blasi F, editors. Mechanisms and management of COPD exacerbations. Milano: Springer-Verlag; 2000. p. 88-99.
39. Grupo de trabajo de la Asociación Latinoamericana del Tórax. Actualización de las recomendaciones ALAT sobre exacerbacion infecciosa de la EPOC. Arch Bronconeumol. 2004;40:315-25.
40. Doll H, Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics. 2005;23:345-63.